Etentamig — Investigational Agent
Bispecific Antibody · Phase 3 · AbbVie
Mechanism of Action
BCMA x CD3 bispecific antibody with a low-affinity CD3 arm designed to reduce cytokine release while redirecting T cells to lyse BCMA-expressing myeloma cells.
Investigational Indications
- Relapsed/refractory multiple myeloma